ALZpath Secures Funding for Blood-Based Biomarker Testing for Alzheimer's Disease Detection
ALZpath, a developer of blood-based diagnostic biomarker testing for Alzheimer's disease detection receives funding from ADDF's
Stay updated with breaking news from Clinical Validation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ALZpath, a developer of blood-based diagnostic biomarker testing for Alzheimer's disease detection receives funding from ADDF's
Health experts have expressed concern over the increasing numbers of persons living with epilepsy disease in Uganda
Sensor-based digital health technologies (DHTs) have been increasingly adopted in clinical research, clinical care, and everyday life, but a lack of...
Going into 2023, investors think the abilities to demonstrate a measurable return on investment and prove technology’s clinical validation will be the most important factors determining the success of digital health companies, according to a recent report, While the ROI factor is a given, it’s a bit more compelling that investors cited clinical validation as a major driver of success. Sunny Kumar, a partner at GSR Ventures, said clinical validation “is the best signal of patient value and historically has been under-captured in digital health.”
Researchers validated monkeypox virus (MPXV) quantitative polymerase chain reaction (qPCR) assays.